MDM2 Inhibition

Emerging Role of MDM2 in Myelofibrosis Care

What is MDM2 and what does it mean for myelofibrosis patients? Watch as Dr. Srdan Verstovsek explains the mechanism of action of the MDM2 inhibitor and which patient population it may benefit.

Published:

Experts Explain MDM2 Inhibition and Clinical Trial for MPN Patients

How does MDM2 inhibition work to treat MPNs? Watch as experts Dr. Srdan Verstovsek and Dr. Jason Gotlib discuss an upcoming MDM2 inhibitor clinical trial for patients living with MF and PV.

Published:

Exclusive Coverage of MDM2 Inhibition: Which MPN Patients Will Benefit?

Cancer researchers identified a promising new target for inhibitor treatment in MPNs – MDM2 – which may allow the cancer cell suppressor gene P53 to reactivate. Watch now to learn more.

Published:

Tap the icon in the top-left corner of the 2019 Clinical Trial Locator Map banner to view map legend.


This program is sponsored by Kartos Therapeutics, Inc. This organization has no editorial control. It is produced solely by Patient Power.

Advertisement
Join Our Community Register for Events Read Our Latest Blog
Advertisement

Page last updated on September 19, 2019